PDE5A and benign prostatic hyperplasia: Taken together, the dual PDE4/PDE5 inhibition profile of compound VIII, combined with its favorable functional effects on smooth muscle tone and cell proliferation, identifies this scaffold as a promising starting point for further optimization toward BPH therapy.